APO-T, LinXis in ADC Alliance

LinXis has granted APO-T an exclusive worldwide license for the development and commercialization of fully-human antibody-drug-conjugates using APO-T’s MAGE-HLA targeted antibodies and LX linker technology. In return, LinXis will receive milestone payments and royalties.
 
“We are excited to license this program from LinXis, a company known for the development of innovative linker technology for the conjugation of cytotoxic drugs to antibodies. We are convinced by the sound scientific data LinXis has built around its linker program and we believe it to be a valuable addition to our proprietary oncology pipeline. The in-licensing strengthens the company’s development pipeline and its intellectual property base,” said Johan Renes, chief executive officer of APO-T.
 
Dr. HendrikJan Houthoff, LinXis’ head of research, said, “APO-T’s molecule portfolio targeting MAGE-HLA has demonstrated considerable promise in preclinical studies, and we look forward to working with APO-T. There is a strong medical need for highly specific and efficacious tumor-targeting treatments and, with the combination of APO-T’s tumor-specific antibodies and our unique linker technology (LX), we are now well suited to develop first-in-class novel therapeutics highly beneficial to cancer patients.”